Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Recommendation of “Buy” from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have been given an average rating of “Buy” by the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $12.6250.

Several research firms have commented on CATX. B. Riley Financial increased their price objective on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Royal Bank Of Canada cut their target price on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 17th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, May 5th. HC Wainwright increased their price target on Perspective Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Finally, BTIG Research reiterated a “buy” rating and set a $14.00 price target on shares of Perspective Therapeutics in a report on Tuesday, March 17th.

Perspective Therapeutics Price Performance

CATX opened at $3.63 on Monday. The firm’s fifty day moving average price is $3.56 and its two-hundred day moving average price is $3.87. Perspective Therapeutics has a 1 year low of $1.96 and a 1 year high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. Sell-side analysts predict that Perspective Therapeutics will post -1.11 EPS for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. boosted its holdings in shares of Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares during the last quarter. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics during the fourth quarter worth about $28,000. nVerses Capital LLC purchased a new stake in Perspective Therapeutics during the fourth quarter worth about $31,000. Abel Hall LLC bought a new stake in Perspective Therapeutics in the first quarter worth about $49,000. Finally, Engineers Gate Manager LP bought a new stake in Perspective Therapeutics in the fourth quarter worth about $35,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.